Stocktoria
COMPUGEN LTD CGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-08-01
COMPUGEN LTD financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $72.8M | $27.9M | $33.5M | $7.5M | $6.0M |
| Gross profit | $63.5M | $19.9M | $31.5M | $6.5M | $5.3M |
| R&D expense | $22.8M | $24.8M | $34.5M | $30.6M | $28.7M |
| Operating income | $31.3M | -$14.9M | -$13.0M | -$35.4M | -$35.1M |
| Income tax | $54,000 | $4.5M | $9.0M | $58,000 | $0 |
| Net income | $35.3M | -$14.2M | -$18.8M | -$33.7M | -$34.2M |
| EPS (diluted) | $0.38 | $-0.16 | $-0.21 | $-0.39 | $-0.41 |
| Operating cash flow | $31.6M | $49.6M | -$35.9M | -$34.1M | -$22.7M |
| Free cash flow | $31.3M | $49.5M | -$36.1M | -$34.6M | -$23.0M |
| Cash & equivalents | $90.6M | $18.2M | $13.9M | $11.1M | $7.8M |
| Total assets | $156.6M | $115.0M | $121.3M | $94.2M | $132.2M |
| Shareholders' equity | $102.7M | $54.9M | $65.6M | $77.7M | $106.7M |
Source: SEC EDGAR filings · CIK 0001119774 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.